Pilocarpine

Pilocarpine

SCHEMBL41890

CCC1C(=O)OCC1Cc1cncn1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1CHRM3

The experimentally established mechanism targets of Pilocarpine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 2/20 1.00
CHRM3 known ✓ P20309 2/20 1.00
LMNA P02545 3/20 1.00
CYP3A4 P08684 3/20 1.00
CHRM5 P08912 3/20 1.00
CHRM4 P08173 2/20 1.00
CYP2C9 P11712 2/20 1.00
CHRM2 P08172 1/20 1.00
CYP2A6 P11509 1/20 1.00
CNR1 P21554 1/20 1.00
HTR2A P28223 1/20 1.00
CYP2A13 Q16696 1/20 1.00
MEN1 O00255 1/20 1.00
USP2 O75604 1/20 1.00
TP53 P04637 1/20 1.00
CYP1A2 P05177 1/20 1.00
ALOX15 P16050 1/20 1.00
ALOX12 P18054 1/20 1.00
NFKB1 P19838 1/20 1.00
MAPK1 P28482 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pilocarpine SCHEMBL188019 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL678045 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL9213198 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL15146 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL3078492 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL725541 0.99 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL1670751 0.99 LMNA (0.97) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL5504377 0.99 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL7076217 0.99 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL4972337 0.99 LMNA (0.97) LMNACYP3A4CHRM5CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724839-A2 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS Mediprint Ophthalmics Inc. (US) 2026-04-15 EP claimed
US-20260090984-A1 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS MEDIPRINT OPHTHALMICS INC. (US) 2026-04-02 US claimed
US-12390130-B2 Wearable device for monitoring bodily fluids INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2025-08-19 US claimed
EP-4565206-A1 OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS REDUCTION AGENT Bausch + Lomb Ireland Limited (IE) 2025-06-11 EP claimed
EP-4555375-A1 METHODS OF MAKING AND USING CONTACT LENSES INCLUDING MEDICAMENTS AND STABILIZERS OF LABILE COMPONENTS SUCH AS DRUGS Doshi, Praful (US) 2025-05-21 EP claimed
US-20250127760-A1 COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING PRESBYOPIA SHENYANG XINGQI PHARMACEUTICAL CO., LTD. (CN) 2025-04-24 US claimed
CN-119595727-A Preparation method of electrochemical biosensor for multi-mode sweat detection 华南理工大学 2025-03-11 CN claimed
CN-118592895-B Anti-pollution wearable sweat sensor based on phase transition protein composite hydrogel and preparation method and application thereof 青岛科技大学 2025-02-11 CN claimed
CN-116350790-B Composition and application thereof in preparation of medicine for treating presbyopia 沈阳兴齐眼药股份有限公司 2025-02-07 CN claimed
US-12178904-B2 Contact lenses including medicaments and methods of making and using same including stabilizers of labile components such as drugs MEDIPRINT OPHTHALMICS INC. 2024-12-31 US claimed
EP-0060451-B1 IONTOPHORETIC ELECTRODE MEDTRONIC, INC. (US) 1986-09-17 EP claimed
EP-0138572-A2 Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same FIDIA S.p.A. (IT) 1985-04-24 EP claimed
EP-0060451-A1 Iontophoretic electrode MEDTRONIC, INC. (US) 1982-09-22 EP claimed
EP-0056420-A1 Ophthalmic gel SCHERING CORPORATION (US) 1982-07-28 EP claimed
US-4281654-A Drug delivery system for controlled ocular therapy ALZA CORPORATION (US) 1981-08-04 US claimed
US-4255415-A COMPRISING A MEDICAMENT, A VINYL ACETATE-VINYL ALCOHOL COPOLYMER, AN ALKALI OR ALKALINE BORATE, AND STERILE WATER; TOPICAL SCHERING CORPORATION (US) 1981-03-10 US claimed
US-4209505-A Pilocarpine mouthwash for dry mouth relief MIKHAIL ADIB R 1980-06-24 US claimed
US-4190642-A Ocular therapeutic system for dispensing a medication formulation ALZA CORPORATION (US) 1980-02-26 US claimed
US-4177256-A Osmotic bursting drug delivery device ALZA CORPORATION (US) 1979-12-04 US claimed
US-4135514-A Osmotic releasing system for administering ophthalmic drug to eye of animal ALZA CORPORATION (US) 1979-01-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260090984-A1 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS RPL26, PCTP, RPS24 CHRM1 2455/4885CHRM3 1421/4885LMNA 1960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.